Jan 27- Medical device maker Abiomed Inc raised its full-year revenue forecast and said the U.S. Food and Drug Administration had approved its heart pump, sending its stock nearly 32 percent in extended trading. Abiomed's heart pump, Impella RP, helps blood circulation for up to 14 days in patients who develop acute right heart failure following implantation,...» Read More
Analyst meetings are usually carefully scripted, dry affairs. It's strictly business and rarely, if ever, does an exec open up and get personal. In the first q and a session at today's Lilly analyst meeting, John Johnson, the head of the company's cancer drug unit and former CEO of ImClone, fielded a question about Erbitux.
On May 8th Dendreon announced an offering of nearly 11 million more shares. Seven months later, on December 8th, DNDN announced another offering, this time for 15 million shares.
I don't often write about micro caps, but given that the broader topic is bioterrorism and specifically something that the whole country was on pins and needles about not too long ago, I'm making an exception.
Monday will be a big day for the biotechnology company Celgene. At 3:45p ET, the embargo will apparently lift on new data for its drug Revlimid in an earlier stage of the blood cancer known as multiple myeloma.
Normally things tend to slow down a bit between Thanksgiving and New Year's Day. But this week alone we've already seen two biopharma partnership deals in as many days. First Pfizer and Protalix and now AstraZeneca and Targacept.
Pfizer today announced it's paying what amounts to chump change (a total of $115 million over time) for the rights to a biotech drug to treat a rare disease. And as I write this, investors are rewarding the world's biggest drug company by making its stock the biggest percentage gainer among the Dow 30.
Genzyme, the biotechnology company already reeling from problems manufacturing its drugs for rare diseases, will soon have a formidable new competitor — the pharmaceutical giant Pfizer.
For the second time in three weeks I'm at a flu vaccine manufacturing plant today. Construction isn't finished on the Novartis site yet, but nonetheless they're doing the formal ribbon-cutting ceremony here in Holly Springs, NC this afternoon.
Earlier this week I reported that Dr. Allen Taylor who ran the Abbott vs. Merck cholesterol drug study, which Abbott's drug Niaspan won, would only say that ABT has paid him more than $10,000 in lecture and consulting fees. But he wouldn't be any more specific than that.
VVUS this morning unveiled positive late-stage test results on the ED pill. The company touts that it takes effect in less than 30 minutes and it's out of your system within six hours or so.
When I do an interview with a clinical trial investigator I typically try to take care of what I call the "housekeeping" at the beginning or end.
Live TV is best when things are happening and news is breaking right now. It's immediate and often, hopefully, more compelling.
The most important new antidiscrimination law in two decades — the Genetic Information Nondiscrimination Act — will take effect in the nation’s workplaces next weekend, prohibiting employers from requesting genetic testing or considering someone’s genetic background in hiring, firing or promotions. The New York Times explaines the ramifications.
For top analysts from investment banks, including JPMorgan and Credit Suisse , or some of their minions, the destination is a cardiology conference where on Monday morning medical researchers are expected to present a study with potentially significant implications for multibillion-dollar cholesterol medications from the drug giant Merck.
It doesn't always happen, but there is a common to-and-fro, push-and-pull, back-and-forth or whatever you want to call it between reporters and corporate PR folks. I don't particularly like that part of my job, but sometimes it just comes with the territory. I've got my job to do and they've got theirs. I get it.
Texas billionaire T. Boone Pickens has made headlines with his clean energy plan for America. But what you haven't heard is the 81-year-old's plan to stay mentally and physically fit. Neuroscientists who have studied his brain say it appears to function like someone half his age.
Today starts a two-day FDA public hearing in Washington, DC on biopharma and social media. I decided not to go because talking heads in a meeting room just don't make for good TV. And this is just the first step in what is no doubt going to be a very long, involved policy-making process. But as it turns out, it looks like it might have been futile for me to try to attend anyway.
Health care reform has always had two main goals. The first — insuring the uninsured — carries grand overtones of social justice. The second — making the health care system more efficient — can seem abstract, technocratic and a bit nerdy. The New York Times looks at what's missing.
When I went to the FDA's Web site today I was surprised to see on the homepage a link to a letter written by Commissioner Dr. Peggy Hamburg. It's addressed to "Dear Healthcare Professional" aka a "Dear Doctor letter." That's a common type of communication from the agency and/or companies to the medical community, usually when they've got bad news to pass along about a drug or device. It's pretty rare for the commish to write one.
As health care legislation moves to the Senate, there is a growing criticism that the measure doesn't fulfill President Obama’s promise to slow runaway health care costs, the New York Times reports.